From Atlanta, at a meeting of the American Society of Hematology
A bone marrow transplant preceded by destruction of one's own bone marrow with radiation or chemotherapy is a bleak prospect for a leukemia patient. Although the procedure can be lifesaving, it carries toxicity risks and weakens the patient. That's why people with autoimmune diseases rarely get a marrow transplant—even though it's potentially curative.
Scientists have now devised a synthetic antibody called ACK2 that targets a protein displayed on the surface of marrow cells and destroys them without radiation or chemo. These marrow cells, also called hematopoietic stem cells, can develop into various immune cells. In autoimmune diseases, some of them run amok and orchestrate tissue damage.